Sotatercept + Background PAH Therapy
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Nov 14, 2024 → Nov 20, 2025
NCT ID
NCT06664801About Sotatercept + Background PAH Therapy
Sotatercept + Background PAH Therapy is a phase 2 stage product being developed by Merck for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT06664801. Target conditions include Pulmonary Arterial Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06925750 | Phase 2 | Active |
| NCT06664801 | Phase 2 | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension